Sort
82,697 grants matching “vaccine development”
Novel Mucosal Adjuvant for an HIV DNA Vaccine
$733,632Kenneth C Bagley · Profectus Biosciences, Inc. · R44 · FY2016 · AI
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies
$733,631James Even Voss · Scripps Research Institute, The · R01 · FY2024 · AI
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
$733,610Klaus J Frueh · Oregon Health & Science University · R01 · FY2018 · AI
Elucidating the functions of red blood cell factors in malaria parasite invasion
$733,590Elizabeth S. Egan · Stanford University · R01 · FY2025 · HL
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)
$733,502Thomas Quinn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Human T cell responses permissive for progression to active TB disease
$733,484Joel D. Ernst · Emory University · U19 · FY2015 · AI
Host Genetics of HIV-1 Subtype C Infection, Progression, and Treatment in Africa
$733,469Myron E Essex · Harvard School Of Public Health · R01 · FY2008 · AI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
$733,450Nora E Sarvetnick · University Of Nebraska Medical Center · R01 · FY2020 · AI
Ontogeny and metabolism of lung alveolar macrophages in tuberculosis
$733,424Lu Huang · Univ Of Arkansas For Med Scis · R01 · FY2025 · AI
Non-Human Primate Core (NHP Core)
$733,400Koen K Van Rompay · Duke University · P01 · FY2019 · AI
Molecular Regulation of B-Cell Differentiation and Function
$733,388Herbert Morse · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis
$733,354Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2017 · AI
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
$733,308Mark Yarchoan · Johns Hopkins University · R01 · FY2022 · CA
Translation Research in Plasmodium vivax
$733,249University Of Valle · P50 · FY2004 · AI
Mechanisms of SIV suppression by CD8+ lymphocytes
$733,243Guido Silvestri · Emory University · R01 · FY2013 · AI
Impact of Fc N-glycan structure on HIV-specific antibody functions
$733,243Donald L. Jarvis · University Of Wyoming · R01 · FY2019 · AI
IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASIS
$733,183David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Evolution of anti-filovirus B cell responses and mechanisms of protection
$733,183M. Javad Aman · Integrated Biotherapeutics, Inc. · R01 · FY2021 · AI
Structures of initial CD4 engagement with pre-fusion, closed HIV-1 Envelope trimer and early CD4-induced conformational changes required for infection
$733,183Priyamvada Acharya · Duke University · R01 · FY2020 · AI
HIV-1 vaccine-elicited antibodies target envelope glycans
$733,115Kevin O Saunders · Duke University · R01 · FY2024 · AI
Development of Efficacious and Stable Nasal Vaccine Formulations
$733,094Herman F. Staats · Duke University · U01 · FY2010 · AI
Antibody Responses in Aging SIV Infected Monkeys
$733,027Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2019 · AI
Columbia University-Southern African AIDS International Training/Research Program
$733,015Quarraisha Abdool Karim · Columbia University Health Sciences · D43 · FY2011 · TW
Skin Vaccination Against Influenza in the Young And Aged
$732,992Richard W Compans · Emory University · R01 · FY2019 · AI
Targeting early metastable intermediates of the SARS-CoV-2 spike for vaccine and therapeutics development
$732,990Priyamvada Acharya · Duke University · R01 · FY2020 · AI